Strawman
Strawman
"Hope is not an investment strategy"
PerformanceCommunity EngagementCommunity Endorsement

Ranked

#3

Followers
628
38.1% pa
Since November 2017
-9.4%
last 3 months
-0.7%
last 6 months
86.1%
last 12 months
Activity feed filter options
Replied to a forum post
21 minutes ago
Expiring trade orders

Excellent, so the easiest thing to do is just change the default expiry to 21 days and then we can add more choice down the track.

Thanks for the feedback and consider it done! (in the next week or so)

Voted on a valuation for Cadence Capital Limited by KoroKoro
23 minutes ago
Justification
Midway between the pre and post tax NTA. (Has a substantial number of franking credits). Plus the announcement today has raised the share price and the NTA significantly.
Voted on a valuation for Xref Limited by Noddy74
23 minutes ago
Justification
XRef's primary business is providing a platform for employers to reference check prospective employees. The reference check is done online so referees can complete it when it suits them, there's potentially less delivery/interpretation bias and its easier to get references from overseas employers. I suppose the downside for employers is there's less opportunity to 'look them in the eye' or drill down further on an answer. They seem to be well liked by their customers (https://www.capterra.com.au/software/157672/xref and https://www.g2.com/products/xref-xref/reviews) and with that positive sentiment I can see how they could get network effects from users from one company moving to another employer and how referees themselves could see the benefit of the product. Having said that it's growing sales but only at a modest rate. I think you have to come to a decision about the extent to which covid is hurting its sales and if you feel it is you could then see how those might accelerate after the global economy recovers. The second half of this Coffee Microcaps meeting is worth looking at. https://youtu.be/GT93XJg5XK8 The good: - Potential for revenues to sharply benefit from global recovery - Steep reduction in cost base with management targeting Q4 21 breakeven . I think that is likely to be a catalyst for SP inflection. - Cashflows should lead revenues given their model is to sell 'credits' to companies, which then don't get recognised as revenue until they're utilised i.e. a prospective employee is reference checked. - State they are developing and implementing new products at a faster rate than any time in their history. The bad: - Is the board sacrificing long term growth for short term incentives? There are a lot of options expiring over the next few years at around 70 cents and the question has to be asked whether the focus on cost reduction is having a longer term impact on sales. - Have adopted a per use model, which will expose them to cyclicality and is going against the current trend towards maximising ARR. Of course that works both ways and if you accept the global recovery argument their model could work to their advantage over the next couple of years. The ugly: - SP - the technicals are horrible. It's been sold off on low volumes for the last couple of months and many would advise waiting, accepting you'll miss the bottom but buying with confidence that you have volume and momentum on your side. The SP outcomes for this one are diverse and depending on how bullish or bearish I'm feeling I can get a DCF to give me a SP anywhere between something (not a given for all companies) and $1. Overall I'm confident enough that it has a feasible product, is very near being cashflow positive and that the risk/reward ratio is skewed such that the downside is limited and the upside is significant. I've taken a position at 24 cents.
Read more
Voted on a valuation for Webjet Limited by MAUOMBO
23 minutes ago
Justification
16PE of a bit of a guess of forward earnings of 20cps
Voted on a straw in #Bull Case for CSL Limited by MrFox
23 minutes ago
#Bull Case

tidbit in AFR today

10 mins ago – 1.31pm

CSL and government working together

Tom McIlroy

Health Department boss Brendan Murphy says the government is working with medical giant CSL to expand production of locally-made vaccine doses.

“It’s a partnership between the Commonwealth and the states. We’re all in this together,” he says.